Condition: Retroperitoneal Sarcoma · Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Surgery is currently the only potentially curative treatment modality for localized retroperitoneal sarcoma (RPS). Available studies regarding oncologic outcomes are mainly retrospective in nature, and RPS are recognized as a rare disease. Therefore, prospective analysis of high quality data is a top priority. Primary Objectives of this study are: * to prospectively collect standardized clinical data and radiological and pathological material from primary RPS patients treated with surgery at reference centers. * patient outcome will be evaluated in terms of overall survival (OS), disease-free survival (DFS), crude cumulative incidence (CCI) of local recurrence (LR) and distant metastasis (DM). Secondary Objectives: * to estimate the efficacy and safety of surgical treatment, including extended surgical approach to primary RPS; * to prospectively evaluate the impact of multimodality therapy, including radiation therapy and chemotherapy; * to identify clinical, radiological and pathological characteristics that may influence the oncological outcome or may be used as predictors of LR/DM/OS. These may be important biomarkers of disease; * to utilize collected pathological material for research collaborations.
This description comes directly from the study's public registry record.
Alessandro Gronchi, MD · +39022390 · alessandro.gronchi@istitutotumori.mi.it
Marco Fiore, MD · +392390 · marco.fiore@istitutotumori.mi.it
Always discuss trial participation with your own doctor first.
| University of Southern California (USC) | Los Angeles, California, United States | Recruiting |
| Mayo Clinic | Jacksonville, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Winship Cancer Institute | Emory, Georgia, United States | Recruiting |
| Brigham and Women's Hospital/Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| The Ohio State University | Columbus, Ohio, United States | Recruiting |
| Peter MacCallum Cancer Center | Melbourne, Australia | Recruiting |
| Maisonneuve-Rosemont Hospital / University of Montreal | Montreal, Canada | Not Yet Recruiting |
| The Ottawa Hospital | Ottawa, Canada | Recruiting |
| Mount Sinai / Princess Margaret | Toronto, Canada | Recruiting |
| Institut Curie | Paris, France | Recruiting |
| University Medical Center and Medical Faculty Mannheim, University of Heidelberg | Mannheim, Germany | Not Yet Recruiting |
+ 10 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03838718